This work was supported in part by the Canadian Institutes for Health Research (CIHR) through U/I grant FRN 59836. We would like to thank John Maraganore for helpful comments.
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo†
Article first published online: 10 JUL 2012
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 34, pages 8529–8533, August 20, 2012
How to Cite
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., Rajeev, K. G., Hafez, I. M., Akinc, A., Maier, M. A., Tracy, M. A., Cullis, P. R., Madden, T. D., Manoharan, M. and Hope, M. J. (2012), Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo. Angew. Chem. Int. Ed., 51: 8529–8533. doi: 10.1002/anie.201203263
- Issue published online: 14 AUG 2012
- Article first published online: 10 JUL 2012
- Manuscript Received: 27 APR 2012
- Funded Access
- Canadian Institutes for Health Research
- CIHR. Grant Number: FRN 59836
- 17Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C). (Registry of Federally and Privately Supported Clinical Trials, U.S. National Institutes of Health, 2011).
- 18A. Simon, Phase I Safety, Pharmacokinetic and Pharmacodynamic Results for ALN-PCS, Preliminary Study Results. (Alnylam Pharmaceuticals, Inc, 2012).